- Home
- COLL vs ELE Comparison
COLL vs ELE Comparison
Compare COLL & ELE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | COLL | ELE |
|---|---|---|
| Founded | 2002 | N/A |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.3B |
| IPO Year | 2015 | N/A |
Fundamental Metrics
Financial Performance| Metric | COLL | ELE |
|---|---|---|
| Price | $45.76 | $20.96 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $51.17 | N/A |
| AVG Volume (30 Days) | 406.2K | ★ 409.1K |
| Earning Date | 02-26-2026 | 03-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 145.82 |
| EPS | ★ 1.63 | 0.21 |
| Revenue | ★ $757,067,000.00 | $33,115,000.00 |
| Revenue This Year | $26.17 | $146.47 |
| Revenue Next Year | $3.65 | $57.23 |
| P/E Ratio | ★ $28.17 | $260.88 |
| Revenue Growth | 26.34 | ★ 124.30 |
| 52 Week Low | $23.23 | $7.80 |
| 52 Week High | $50.79 | $26.96 |
Technical Indicators
Market Signals| Indicator | COLL | ELE |
|---|---|---|
| Relative Strength Index (RSI) | 46.77 | 54.80 |
| Support Level | $43.99 | $19.76 |
| Resistance Level | $49.31 | $22.00 |
| Average True Range (ATR) | 1.62 | 1.98 |
| MACD | -0.12 | -0.18 |
| Stochastic Oscillator | 38.19 | 31.76 |
Price Performance
Historical ComparisonAbout COLL Collegium Pharmaceutical Inc.
Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Jornay, Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.
About ELE Elemental Royalty Corporation
Elemental Royalty Corp is engaged in exploration discovery, royalty generation, royalty acquisition, and strategic investments.